Therapy Area Reports

Learn More Renal Cell Carcinoma: Update Bulletin [September 2017]

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; data released from Bristol-Myers Squibb’s Phase III CheckMate-214 study,...

Compare
Learn More Multiple Myeloma: Update Bulletin [September 2017]

This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; positive topline results from the Phase III study ALCYONE of Johnson &...

Compare
Learn More Rheumatoid Arthritis: Update Bulletin [September 2017]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson...

Compare
Learn More Payer Insights: RA : Update Bulletin [August 2017]

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent approvals for biosimilar rituximab products in Europe Celltrion/Mundipharma’s Truxima...

Compare
Learn More Melanoma: KOL Insight: Update Bulletin [August 2017]

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma submission of two New Drug Applications (NDAs) to the US Food and...

Compare
Learn More HNSCC: Update Bulletin [August 2017]

Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC): data from the Phase I/II ECHO-202/KEYNOTE-037 study of Incyte’s IDO1 inhibitor epacadostat in combination with...

Compare
Learn More Breast Cancer: Update Bulletin [August 2017]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY...

Compare
Learn More NASH: Update Bulletin [August 2017]

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the recent...

Compare
Learn More Multiple Sclerosis: Update Bulletin [August 2017]

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche...

Compare
Learn More Acute Myeloid Leukaemia: Update Bulletin [August 2017]

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics covered include expert opinions on; Seattle Genetics reporting the...

Compare
Learn More Cystic Fibrosis: Update Bulletin [August 2017]

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; Anthera Pharmaceuticals announcing that it has commenced...

Compare
Learn More CAR-T Therapy in Haematological Malignancy: Update Bulletin [July 2017]

This edition presents US and EU key opinion leader (KOL) views on recent developments in the CAR-T therapy space. Topics covered include expert opinions on Novartis receiving a positive recommendation from the...

Compare
Learn More COPD: Update Bulletin [July 2017]

Gain new key opinion leader (KOL) insights on the latest events happening in COPD. Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate), delivered via PARI's investigational eFlow...

Compare
Learn More Ovarian Cancer: Update Bulletin [July 2017]

This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib)...

Compare
Learn More Prostate Cancer: Update Bulletin [July 2017]

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating...

Compare
Learn More Targeted Therapies in Asthma: Update Bulletin [July 2017]

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the severe asthma treatment landscape. Topics covered include; Novartis...

Compare
Learn More Colorectal Cancer: Update Bulletin [June 2017]

This edition presents key opinion leader (KOL) views on recent developments in the Colorectal Cancer (CRC) market. Topics covered include: Bristol-Myers Squibb (BMS) announcing interim data from the Phase II,...

Compare
Learn More Rheumatoid Arthritis: Update Bulletin [June 2017]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of rheumatoid arthritis (RA). Topics covered include; KOL views on the Food and Drug Administration’s issuance of a...

Compare
Learn More Ulcerative Colitis: Update Bulletin [June 2017]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world...

Compare
Learn More Type 2 Diabetes Mellitus KOL Insight : Update Bulletin [June 2017]

This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line results from the Phase...

Compare

Browse by